RT Journal Article
SR Electronic
T1 Public Health and Health Systems Impacts of SARS-CoV-2 Variants of Concern: A Rapid Scoping Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.20.21257517
DO 10.1101/2021.05.20.21257517
A1 Curran, J
A1 Dol, J
A1 Boulos, L
A1 Somerville, M
A1 McCulloch, H
YR 2021
UL http://medrxiv.org/content/early/2021/05/22/2021.05.20.21257517.abstract
AB Background As of April 2021, three SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351 and P.1) have been detected in over 132 countries. Increased transmissibility of VOC has implications for public health measures and health system arrangements. This rapid scoping review aims to provide a synthesis of current evidence related to public health measures and health system arrangements associated with VOC.Methods Rapid scoping review. Seven databases were searched up to April 7, 2021 for terms related to VOC, transmission, public health and health systems. A grey literature search was conducted up to April 14, 2021. Title, abstracts and full text were screened independently by two reviewers. Data were double extracted using a standardized form. Studies were included if they reported on at least one of the VOC and public health or health system outcomes.Results Of the 2487 articles and 59 grey literature sources retrieved, 37 studies and 21 guidance documents were included. Included studies used a wide range of designs and methods. Most of the studies and guidance documents reported on B.1.1.7, and 18 studies and 4 reports provided data for consideration in relation to public health measures. Public health measures, including lockdowns, physical distancing, testing and contact tracing, were identified as critical adjuncts to a comprehensive vaccination campaign. No studies reported on handwashing or masking procedures related to VOC. For health system arrangements, 17 studies were identified. Some studies found an increase in hospitalization due to B.1.1.7 but no difference in length of stay or ICU admission. Six studies found an increased risk of death ranging from 15-67% with B.1.1.7 compared non-B.1.1.7, but three studies reported no change. One study reported on the effectiveness of personal protective equipment in reducing VOC transmission in the hospital. No studies reported on screening staff and visitors, adjusting service provisions, or adjusting patient accommodations and shared spaces, which is a significant gap in the literature. Guidance documents did not tend to cite any evidence and were thus assumed to be based on expert opinion.Conclusion While the findings should be interpreted with caution as most of the sources identified were preprints, findings suggest a combination of non-pharmaceutical interventions (e.g., masking, physical distancing, lockdowns, testing) should be employed alongside a vaccine strategy to improve population and health system outcomes. While the findings are mixed on the impact of VOC on health system arrangements, the evidence is trending towards increased hospitalization and death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is support by: The SPOR Evidence Alliance (SPOR EA), which is supported by the Canadian Institutes of Health Research (CIHR) under the Strategy for Patient-Oriented Research (SPOR) initiative, and the COVID-19 Evidence Network to support Decision-making (COVID-END), which is supported by the Canadian Institutes of Health Research (CIHR) through the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding opportunity.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethical approval was required as it is a review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon reasonable request from corresponding author.ABMAgent-based ModelAGREE IIAppraisal of Guidelines Research and EvaluationaIRRadjusted incidence rate ratiosB.1.1.7variant of concern originating in the United Kingdom, also known as VUI 202012/01 and VOC 202012/01B.1.351variant of concern originating in South Africa, also known as 20H/501Y.V2BMIbody mass indexCanCOGenCanadian COVID Genomics NetworkCENTRALCentral Register of Controlled TrialsCFRCase Fatality RatesCIconfidence intervalCIDRAPCenter for Infectious Disease Research and PolicyCtcycle threshold, provides a relative measure of viral quantityCOG-UKCOVID-19 Genomics UKCDSRCochrane Database of Systematic ReviewsdQALYdiscounted quality-adjusted life yearsE484Kescape mutation in the SARS-CoV-2 virus, present in B.1.1.7ECDCEuropean Centres for Disease ControlFDAFood and Drug AdministrationHCWhealthcare workersHRHazard RatioHVACheating, ventilation, and air conditioningICUIntensive Care UnitIQRinterquartile rangeIRincidence rateLOSlength of staymRNAmessenger ribonucleic acidNGSnext generation sequencingNOSNewcastle-Ottawa scaleNPINon-Pharmaceutical InterventionsNRWNorth-Rhine WestphaliaORodds ratioP.1variant of concern originating in Brazil, also known as B.1.28.1PCRpolymerase chain reaction, method for DNA replication and genome sequencingPHUPublic Health UnitPPEpersonal protective equipmentPRprevalence ratioRreproductionR0basic reproduction number, expected number of cases generated by one case in a population when everyone is susceptible to infectionRteffective reproduction numberRRrisk ratioRT-LAMPreverse transcription loop-mediated and transcription-mediated amplification isothermal amplificationRTDRapid Antigen TestSASouth AfricaSAPSIIseverity score at admissionSIDARTHEa type of modelSGTFspike OR S gene target failure, correlates with the increase of confirmed, sequenced variantsSGTLspike gene late detectionSDstandard deviationUKUnited KingdomUSUnited StatesVEvaccine efficiencyVOCvariant of concernWHOWorld Health OrganizationWGSwhole genome sequencing